AlphaYouCY
Insider selling
Christopher Yea sold $905K of KalVista Pharmaceuticals, Inc. (KALV) stock
Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, Inc. (KALV), sold 33,800 shares of KALV stock worth $905K, per an SEC Form 4 filed May 29, 2026.
The sale was pre-arranged (a 10b5-1 plan or an option exercise), not a fresh decision.
The trade happened on May 27, 2026, 2 days before it was made public.
- Traded
- May 27, 2026
- Disclosed
- May 29, 2026
- Filing delay
- 2 days
- Role
- Chief Development Officer
- Source
- SEC Form 4
More KALV insider and Congress trades
From a public SEC Form 4, linked above. Not investment advice, and not a recommendation to buy or sell.